Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Changes in Relais Group Management Team

Relais Group Plc, Company Release 11 August 2022 at 9.30 a.m. EEST  The following persons have been appointed to the Group Management Team of Relais Group Plc as of 11 August 2022: Johan Carlos (b. 1990), Managing Director Strands Group AB. Johan has been the Managing Director of Strands Group since 2017 and prior to that had various positions in sales and marketing at the company since 2010. Jan Popov (b. 1989), LLM, Managing Director Raskone Oy. Jan has been Managing Director of Raskone since 2018. Prior to that he worked as M&A lawyer at Eversheds Sutherland. Sebastian

Good things are worth waiting for - welcome to the second half of 2022!

We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that will investigate the postoperative analgesic efficacy of CT001.We obtained regulatory approval by the authorities and thereby green light at the end of June and have since then prepared the site and involved dental clinics. We are ready and hope to announce first patient within a few weeks. This will basically take the company to the next level as not that many companies are in a late-stage clinical development...Upcoming top line results of Trial 0206

Nightingale Health’s Board of Directors resolved on a change to the share-based incentive schemes

Company release, 11 August 2022 at 9:30 a.m. (EEST) Nightingale Health Plc’s (“Nightingale Health”) Board of Directors resolved to change the subscription price of shares in the company’s stock option programs. The change is applicable in all stock option programs that entitle to subscribe for Series B shares.   The new subscription price of each share in the stock option programs is EUR 2.50. Prior to the change the subscription price was EUR 6.75 per share. The subscription price is changed to maintain the purpose of the stock option programs to incentivise the option holders to

XMReality Interim report, Group overview, April – June 2022

The Annual Recurring Revenues (ARR) increased 3 percent. The Net Sales decreased by 17 percent. The Gross Margin rose from 90 percent to 95 percent.The Quarter April – June 2022, The Group · Net sales amounted to SEK 4,616 thousand (5,565) · Costs totaled SEK -18,431 thousand (-13,909) · The operating loss before appropriations and taxes was SEK -9,395 thousand (7,749) · Cash flow was SEK -12,349 thousand (-6,206) and the equity/assets ratio at the end of the period was 60.6 (80.0) percent Net sales decreased with 17 percent to SEK 4,616 thousand (5,565). The Annual

Notice to Extraordinary General Meeting in SameSystem A/S

Company Announcement No. 17-2022Copenhagen, 11 August 2022 The shareholders of SameSystem A/S are hereby convened to an extraordinary general meeting scheduled for 26 August 2022 at 14:00 am. With reference to company announcement no. 10-2022, election of new members of the board of directors is on the agenda. Please refer to the notice attached. Also, with reference to company announcement no. 10-2022, the Board of Directors has assessed the possibility of a strategic merger or sales process, including the engagement of a corporate finance advisor and discussed the options

Ruukki to invest in Nordic PIR sandwich panel production

Ruukki Construction, part of SSAB Group, is to invest EUR 15 million in sandwich panel production in Borlänge, Sweden. The new production line will be the first in Scandinavia to produce PIR sandwich panels tailored to the needs of Nordic customers. The production will come on stream in Q3 2024. Ruukki offers its customers sustainable solutions for wall and roof structures. The new production line to be built in Borlänge, Sweden will strengthen Ruukki's ability to serve customers locally in the Nordics by providing them with a dedicated product portfolio. The change will also

Aker Solutions to Provide Subsea Production System for the Trell & Trine Development

August 11, 2022 – Aker Solutions has been awarded a sizeable[1] contract from Aker BP to provide the subsea production system for the Trell & Trine field development, located in the Alvheim area of the North Sea. The development concept is a subsea tie-back to the Alvheim FPSO, using existing facilities and infrastructure.Aker Solutions will deliver a subsea production system including three horizontal subsea trees, two manifolds, control systems, close to 30 kilometers of subsea umbilicals, as well as associated equipment and installation work. The work will start immediately with final

Acquisition of TeneoTwo completed

11 August 2022 07:00 BST Acquisition of TeneoTwo for its clinical-stage T-cell engager completed AstraZeneca has completed the acquisition of TeneoTwo, Inc . (TeneoTwo)[i], including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.[1] AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. Financial considerations

Flexion Mobile signs agreement with Clicktouch to launch hit game in Japan

LONDON, 11th of August 2022 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company has signed an agreement with Clicktouch Co., Ltd. to publish Call Me Emperor (アイアム皇帝) on the alternative app stores.  Flexion will distribute the hit game on Amazon Japan in September 2022. Call Me Emperor already earns US$6 million in monthly gross revenue on Google Play according to the developer’s data.  Flexion’s distribution services will add revenue and new players from the alternative app stores with little upfront cost or work being required of the developer. Flexion is adding

Anora invests in ISH, the award-winning Danish scale-up company in non-alcoholic beverages

Anora has made an investment of EUR 5 million in ISH, the Danish scale-up company in non-alcoholic beverages, making Anora a minority shareholder in the company. The investment will enable ISH to further accelerate its international growth. Anora will be distributing ISH’s alcohol-free products in Norway, Sweden, and Finland. The agreement between Anora and ISH was completed on 20 July 2022.ISH is a global leader in non-alcoholic (NA) markets with a broad portfolio of award-winning non-alcoholic spirits, wines and ready-to-drink beverages. The company was founded in 2018 on the premise that

UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis

· Topline results expected in first half of 2023 · Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD)   Hellerup, Denmark, 11 August 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces that it has completed enrollment of the last patient in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of

Successfully focusing on core business

STOCKHOLM – 12 of August 2022 – ContextVision, a medical technology software company specializing in image processing, delivered the Company’s best ever second quarter revenue numbers and a significant EBITDA increase. Sales in the second quarter reached MSEK 32,5 (24.4), an 19% increase compared with the previous quarter, and an increase of 26% versus last year’s corresponding quarter when adjusted for currency exchange effects. EBITDA reached MSEK 15,5 (11,4). The revenue increase is coming from new strategic contracts as well as expanding on current contracts with existing

Acroud publishes interim report Apr-Jun 2022: Continued strong organic growth with refinancing secured

Second Quarter 2022   · Revenue amounted to EUR 7 200 (6 200) thousand, corresponding to a growth of 16% and an organic growth of 15%.    · EBITDA amounted to EUR 1 802 (1 159) thousand, increasing by 55% year-on-year. Adjusted EBITDA (before items affecting comparability) was EUR 1 802 (1 500) thousand, increasing by 20% year-on-year.    · Profit after tax was EUR 1 248 (-267) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR 588 (292) thousand.   · Earnings per share after dilution amounted to EUR 0.010 (

Relais Group Plc Half-year financial report January–June 2022 (unaudited)

Relais Group PlcCompany release 11 August 2022, 9:00 a.m. EEST This release is a summary of Relais Group's Half-year financial report January–June 2022. The full release is attached to this company release and is available on our website at https://relais.fi/en/investors/. APRIL–JUNE 2022 IN BRIEF · Net sales totaled EUR 58.6 million (April – June 2021: 52.2), +12.2% change · EBITDA was EUR 4.2 (5.4) million, 7.2% (10.3%) of net sales, -21.3% change · EBITA was EUR 3.7 (4.8) million, 6.4% (9.2%) of net sales, -22.6% change · EBIT was EUR -0.0 (1,5) million, -0.1% (2.9%)

Oncopeptides publishes Q2 report 2022

STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quarter 2022.“CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides says Jakob Lindberg, CEO of Oncopeptides. “This is excellent news for patients, shareholders, and for the future development of Oncopeptides.” Financial overview April-June · Net sales amounted to SEK 8.8 M (66.4) ·

FlexQubes report for the second quarter 2022

SECOND QUARTER 2022 · Order intake increased by 69.3 percent to 54.9 MSEK (32.4). Adjusted for foreign exchange rate effects between the comparison periods, order intake increased by 47.2 percent. · Net sales increased by 111.4 percent to 56.1 MSEK (26.5). Adjusted for foreign exchange rate effects between the comparison periods, net sales increased by 89.3 percent. · Operating profit before depreciation (EBITDA) amounted to 1.5 MSEK (-1.6) and operating profit before financial items (EBIT) amounted to 0.3 MSEK (-2.7). · Profit before tax amounted to 0.2 MSEK (-2.8). ·

Transcom Holding AB (publ): Invitation to Transcom second quarter 2022 results presentation webcast

Transcom are pleased to invite you to their Q2 2022 financial update webcast on Thursday, August 25, at 9:00 am CET, following the release of Q2 2022 results at 8:00 am CET. The Q2 report and presentation will be available on https://www.transcom.com/global/about-us/investor-relations. Representing Transcom Jonas Dahlberg, President & CEOSnejana Koleva, CFO Presentation details Date/Time: Thursday, August 25, at 9:00 am CETOnline Registration link: https://app.livestorm.co/transcom-holding/transcom-holding-ab-q2-2022-results-presentation   Important note: Please register

Olvi Group’s half-year report 1 January to 30 June 2022 (6 months)

OLVI PLC                  Half-year report 11 August 2022 at 9 am Olvi Group’s half-year report 1 January to 30 June 2022 (6 months) Half-year report in brief Olvi Group’s sales volume and net sales developed strongly during the second quarter, in line with the favourable trend that prevailed in the first quarter. The Group’s operating profit decreased during the review period, but the previous year’s level was achieved in the second quarter despite significant and rapid cost increases. The impact of higher costs has been successfully reduced through price increases in all markets.

H+H International A/S to present H1 2022 Interim Financial Report

H+H International A/S expects to release its interim financial report for the first six months of 2022 (“H1 2022”) on Thursday 18 August 2022. In connection with the release of the H1 2022 Interim Financial Report, a conference call for investors and analysts is scheduled for Friday 19 August 2022 at 10:00 a.m. CEST. On the call, CEO Michael T. Andersen and CFO Peter Klovgaard-Jørgensen will present the interim financial report. The presentation will be followed by a Q&A session. Investors and analysts are invited to participate via phone (PIN code: 275042): DK: +45 78768490UK:

Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

AQILION AB (publ) announces today that the Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super selective JAK1 small molecule inhibitor that is under development for indications within chronic inflammatory diseases. Aqilion has thus reached a very important milestone as the company has managed to take the big step from preclinical phase to clinical Phase 1.  The Phase 1 clinical trial, ARIA-1, will include 64 healthy volunteers. The purpose of the study is to

Nixu Corporation’s Half-Year Financial Report 2022: Positive business development continued with 7% growth

Nixu Corporation, Stock Exchange Release on August 11, 2022 at 8:30 a.m. EESTThis release is a summary of the Nixu Corporation’s January 1 – June 30, 2022 Half-Year Financial report. The complete report is attached to this release as a pdf-file. It is also available on the company website at https://www.nixu.com/H12022. Highlights for January–June 2022 • Revenue: EUR 28,580 thousand (26,720), change 7%. • EBITDA: EUR 377 thousand (805), share of revenue: 1% (3%). • Adjusted EBITDA: EUR 352 thousand (1,198), share of revenue: 1% (5%). • EBIT: EUR -553 thousand (-154), share of

Anders Fogelberg intends to quit as CEO at FlexQube and take a new role in the company

After nine years as CEO and as a natural step in the company's next phase to become a leading global robotics and automation company, Anders Fogelberg has decided, in agreement with the Board to leave the role as CEO and instead further strengthen FlexQube's continued expansion, with a focus on global strategy, sales and business development. Anders will remain as CEO until a new CEO has been recruited and will then remain in the company and continue the work of driving sales development and strategy of the company's products and customers on the international market. Recruitment of a

Teleste corporation half year financial report 1 january to 30 june 2022: Strong demand continued, but the result declined due to component supply shortages

TELESTE CORPORATION    HALF YEAR FINANCIAL REPORT     11 AUGUST 2022 AT 8:30 EET   TELESTE CORPORATION HALF YEAR FINANCIAL REPORT 1 JANUARY TO 30 JUNE 2022     STRONG DEMAND CONTINUED, BUT THE RESULT DECLINED DUE TO COMPONENT SUPPLY SHORTAGES     April-June 2022   - Net sales amounted to EUR 38.4 (35.8) million, an increase of 7.2% - The adjusted operating result was EUR 0.3 (1.1) million, a decrease of 70.2% - The operating result was EUR 0.2 (1.1) million, a decrease of 83.0% - Adjusted earnings per share were EUR -0.07 (0.04), a decrease of 261.5%

Significantly improved results and good revenue growth

Readly International AB (publ) presents a second quarter with significantly improved results and good revenue growth. Gross profit increased by 30.8 percent to SEK 48.8 (37.3) million, corresponding to a gross margin of 33.8 percent. Adjusted for items affecting comparability of SEK -2.5 million, the EBITDA margin improved to -13.7 (-46.5) percent and the operating margin to -17.8 (-49.0) percent in the quarter. Gross contribution improved to SEK 29.0 (-11.5) million, corresponding to a positive gross contribution margin of 20.1 (-10.4) percent. The number of fully paying subscribers

There are no items matching the current filter
There are no more items matching the current filter
Back to top